Sign in
Active, not recruitingPhase 2

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Key facts

Who runs it
Ono Pharmaceutical Co., Ltd.
Where
Ann Arbor, Atlanta, Boca Raton, Boston, Cincinnati, Cleveland, Columbus, Dallas, Englewood, Farmington Hills, Fountain Valley, Gainesville, Hershey, Jacksonville, Kansas City, Kirkland, Los Angeles, Miami, New Haven, New York, Omaha, Palo Alto, Philadelphia, Richmond, Rochester, and Seattle, United StatesSee the 30 sitesAlso in 1 other country, 5 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
92 people enrolled
Started
22 Sept 2023
Expected to end
31 Oct 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ONO-2808
  • Placebo
Record updated
6 October 2026

Who can take part

Age
30 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Female or male patients with a diagnosis of clinically-established or clinically-probable MSA according to the novel Movement Disorder Society (MDS) criteria for MSA diagnosis (2022), including patients with MSA of either subtype (MSA-P or MSA-C)
  • Patients at the early stages of the disease, defined as a maximum of 5 years since the onset of one of the following symptoms associated with MSA:; Parkinsonism; Ataxia; Orthostatic hypotension and/or urinary dysfunction
  • Patients with an anticipated survival of at least 3 years in the opinion of the Investigator
  • Patients who are able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps and then to turn around and walk at least another 10 steps. Use of assistive devices (e.g., walker or cane) is allowed
  • Ability to swallow oral medication and be willing to adhere to the study intervention regimen

Who cannot take part

  • Patients with suicide ideation according to the Investigator's clinical judgment per the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening or who have made a suicide attempt in the 6 months before Screening
  • Patients with a clinically-significant or unstable medical or surgical condition other than MSA that, in the opinion of the Investigator, might preclude safe completion of the study or might affect the results of the study (e.g., pulmonary, cardiovascular [including bradyarrhythmia], macular edema, and significant renal or hepatic dysfunction)
  • Neurological diseases/disorders other than MSA, such as Parkinson's disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, normal pressure hydrocephalus, pharmacological, or post-encephalitic parkinsonism
  • Patients with documented liver diseases or cirrhosis
  • Positive results at Screening for active viral infections that include positive human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and hepatitis B core antibody, and hepatitis C virus (HCV)
  • Pregnant or lactating females

Where in United States

Also in 1 other country, 5 sites

  • University of Michigan School of MedicineAnn Arbor, United States
  • Emory University School of MedicineAtlanta, United States
  • Parkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, United States
  • Brigham and Women's HospitalBoston, United States
  • Massachusetts General HospitalBoston, United States
  • University of Cincinnati College of MedicineCincinnati, United States
  • Cleveland ClinicCleveland, United States
  • Ohio State UniversityColumbus, United States
  • UT Southwestern Medical CenterDallas, United States
  • CenExel Rocky Mountain Clinical ResearchEnglewood, United States
  • QUEST Research InstituteFarmington Hills, United States
  • The Parkinson's Movement and Disorder InstituteFountain Valley, United States
  • Norman Fixel Institute for Neurological Diseases - University of FloridaGainesville, United States
  • Penn State University Milton S. Hershey Medical CenterHershey, United States
  • Mayo Clinic in FloridaJacksonville, United States
  • University of Kansas Medical Center Research InstituteKansas City, United States
  • Evergreen HealthKirkland, United States
  • David Geffen School of Medicine at UCLALos Angeles, United States
  • University of Southern CaliforniaLos Angeles, United States
  • University of Miami Miller School of MedicineMiami, United States
  • Yale School of Medicine - Yale Church Street Research Unit (CRSU)New Haven, United States
  • Columbia UniversityNew York, United States
  • Icahn School of Medicine at Mount SinaiNew York, United States
  • NYU Langone Health NYU Dysautonomia CenterNew York, United States
  • University of Nebraska Medical CenterOmaha, United States
  • Stanford University, School of MedicinePalo Alto, United States
  • The University of Pennsylvania - Pennsylvania HospitalPhiladelphia, United States
  • Virginia Commonwealth University Medical CenterRichmond, United States
  • Mayo Clinic - RochesterRochester, United States
  • Swedish Neuroscience Institute, Movement Disorders ClinicSeattle, United States

About the trial

What the trial wants to find out

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

The 2 groups in the trial

  • ONO-2808 ArmTreatment being tested

    Treatment: ONO-2808

  • Placebo ArmPlacebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy
Record updated
6 October 2026